Complementary function of the two catalytic domains of APOBEC3G. (Q45274484)

11 December 2017

title

Complementary function of the two catalytic domains of APOBEC3G. (English)

1 reference

11 December 2017

4

Renate König

1 reference

11 December 2017

Francisco Navarro

1

1 reference

11 December 2017

Brooke Bollman

2

1 reference

11 December 2017

Hui Chen

3

1 reference

11 December 2017

Qin Yu

5

1 reference

11 December 2017

Kristopher Chiles

6

1 reference

11 December 2017

Nathaniel R Landau

7

1 reference

11 December 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

11 December 2017

1 reference

11 December 2017

volume

333

1 reference

11 December 2017

issue

2

1 reference

11 December 2017

page(s)

374-386

1 reference

Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Cytidine deamination of retroviral DNA by diverse APOBEC proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

The interaction between HIV-1 Gag and APOBEC3G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

DNA deamination mediates innate immunity to retroviral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Dimeric structure of a human apolipoprotein B mRNA editing protein and cloning and chromosomal localization of its gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Hypermutation of HIV-1 DNA in the Absence of the Vif Protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Functional domains of APOBEC3G required for antiviral activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Isolation, tissue distribution, and chromosomal localization of the human activation-induced cytidine deaminase (AID) gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Evolutionary origins of apoB mRNA editing: catalysis by a cytidine deaminase that has acquired a novel RNA-binding motif at its active site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

A transient three-plasmid expression system for the production of high titer retroviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Inhibition of hepatitis B virus replication by APOBEC3G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

APOBEC3G incorporation into human immunodeficiency virus type 1 particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

Specificity of retroviral RNA packaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

inferred from DOI database lookup

7 January 2021

based on heuristic

A third-generation lentivirus vector with a conditional packaging system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.01.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2005.01.011

1 reference

11 December 2017

1 reference